Clinical and Vaccine Immunology · 2015 · 10 citations · 21 references
MedicineInfectious DiseasesPreventive MedicineClinical ImmunologyDiagnostic MicrobiologyEarly DetectionAntigen Detection AssaysDiagnostic EvaluationDiagnostic Test EvaluationPathogen DetectionSerological DiagnosticsSexually Transmitted InfectionsHigh-volume ApplicationScreening Test SelectionScreening Test ValiditySensitivitySerological DetectionSyphilis DiagnosticsSyphilis ScreeningValidation Of Diagnostic Tests
The resurgence of syphilis in recent years has become a serious threat to public health worldwide, and the serological detection of specific antibodies against Treponema pallidum remains the most reliable method for laboratory diagnosis of syphilis. This study examined the performance of the recently launched HISCL anti-Treponema pallidum (anti-TP) assay as a screening test for syphilis in a high-volume laboratory. The HISCL anti-TP assay was tested in 300 preselected syphilis-positive samples, 704 fresh syphilis-negative samples, 48 preselected potentially interfering samples, and 30 "borderline" samples and was compared head to head with the commercially available Lumipulse G TP-N. In this study, the HISCL anti-TP assay was in perfect agreement with the applied testing algorithms with an overall agreement of 100%, comparable to that of Lumipulse G TP-N (99.63%). The sensitivity and specificity of the HISCL anti-TP assay were 100% (95% confidence interval [CI], 98.42% to 100%) and 100% (95% CI, 99.37% to 100%), respectively. Considering the excellent ease of use and automation, high throughput, and its favorable sensitivity and specificity, the HISCL anti-TP assay may represent a new choice for syphilis screening in high-volume laboratories.
21
IUSTI: 2008 European Guidelines on the Management of Syphilis
Patrick French, M.A. Gomberg, M. Janier et al. · International Journal of STD & AIDS · 2009 · 294 citations